Business Segment Information (Tables)

6 Months Ended

Mar. 31, 2014

Reconciliation from Segment Totals to Consolidated [Abstract]

Reconciliation of Revenue from Segments to Consolidated [Table Text Block]

	Revenue
	Three months ended				Six months ended
	March 31,				March 31,
	2014		2013		2014		2013
Pharmaceutical Distribution	$	27,932,495	$	20,054,159	$	56,555,086	$	40,653,207
Other		572,503		514,942		1,176,635		1,019,992
Intersegment eliminations		(49,095)		(45,433)		(99,456)		(89,720)
Revenue	$	28,455,903	$	20,523,668	$	57,632,265	$	41,583,479

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Operating Income
	Three months ended				Six months ended
	March 31,				March 31,
	2014		2013		2014		2013
Pharmaceutical Distribution	$	372,929	$	321,077	$	659,711	$	587,754
Other		43,633		34,935		79,583		64,660
Total segment operating income		416,562		356,012		739,294		652,414
Gains on antitrust litigation settlements		849		3,456		21,872		15,764
LIFO (expense) credit		(102,828)		215		(160,410)		(952)
Acquisition related intangibles
amortization		(5,825)		(6,098)		(11,783)		(12,197)
Warrants		(5,663)		(3,761)		(121,960)		(3,761)
Employee severance, litigation and other		(1,967)		299		(6,269)		(1,705)
Operating income		301,128		350,123		460,744		649,563
Other (income) loss		(3,783)		749		(4,380)		726
Interest expense, net		19,474		18,510		38,306		37,035
Income from continuing operations
before income taxes	$	285,437	$	330,864	$	426,818	$	611,802